ONCY ONCOLYTICS BIOTECH INC
NEUTRAL
Impact: 2/10
8-K
8-K context-dependent: Items 5.02, 8.01
Latest settled — T+1d ⚠ clustered
ONCY ▼ -5.38% at T+1d
NEUTRAL call ✗ call lost -5.38% · α vs SPY -4.68% · entry $0.9300 → $0.8800
Currently $0.8362 · -10.09% from $0.9300 entry
T+1d
-5.38%
call -5.38% · α -4.68%
$0.8800
settled 2d ago
T+5d
—
call — · α —
—
in 4d
T+20d
—
call — · α —
—
in 26d
T+60d
—
call — · α —
—
in 3mo
Price Chart
Loading chart...
Executive Summary
Oncolytics Biotech announced the appointment of Stephen Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer. This is a routine organizational change with no material financial impact.
Actionable Insight
Monitor for any future partnership or clinical milestones; the board addition and COO promotion suggest a focus on operational execution and strategic transactions, but the filing itself contains no near-term catalyst.
Key Facts
- Stephen Glover appointed as independent director, granted option to purchase 96,000 shares vesting over 3 years.
- John McAdory promoted to COO, previously EVP of Strategy and Operations; no additional compensation.
- Glover brings public company board and M&A experience, including chairing Ambrx during its $2B acquisition by J&J.
Financial Impact
No financial figures disclosed; director option grant is standard compensation.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (8 analysts)
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000039 |
| Document: oncybodandcoo.htm | 0001129928-26-000039 |
| Document: 0001129928-26-000039-index-headers.html | 0001129928-26-000039 |
| Document: 0001129928-26-000039-index.html | 0001129928-26-000039 |
| Document: 0001129928-26-000039.txt | 0001129928-26-000039 |
11 reports for ONCY
57%
Hit rate
best @ T+5▲ +10.53%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
3d ago
|
8-K
| $0.9300 $0.8800 | ▼ −5.38% | ▼ −4.68% | $0.8362 (−10.09%) |
|
Jun 1, 2026
4d ago
|
8-K
| $1.06 $0.9300 | ▼ −12.26% | ▼ −12.41% | $0.8362 (−21.11%) |
|
May 22, 2026
14d ago
|
8-K
| $0.8100 $0.8100 | · 0.00% | ▼ −0.59% | $0.8362 (+3.23%) |
|
May 22, 2026
14d ago
|
Press Release
| $0.8100 $0.8100 | · 0.00% | ▼ −0.59% | $0.8362 (+3.23%) |
|
Apr 27, 2026
5w ago
|
8-K
| $0.9700 $0.9000 | ▼ −7.22% | ▼ −6.73% | $0.8362 (−13.79%) |
|
Apr 6, 2026
8w ago
|
424B5
| $0.9000 $0.9100 | ▼ −1.11% | ▲ +1.43% | $0.8362 (+7.09%) |
|
Apr 6, 2026
8w ago
|
8-K
| $0.9500 $0.9000 | ▼ −5.26% | ▼ −5.33% | $0.8362 (−11.98%) |
|
Apr 6, 2026
8w ago
|
EFFECT
| $0.9500 $0.9000 | ▲ +5.26% | ▲ +5.33% | $0.8362 (+11.98%) |
|
Apr 1, 2026
9w ago
|
S-3
| $0.9300 $0.9600 | ▼ −3.23% | ▼ −3.15% | $0.8362 (+10.09%) |
|
Mar 11, 2026
12w ago
|
Insider Cluster
| $1.01 $0.9600 | ▼ −4.95% | ▼ −3.47% | $0.8362 (−17.21%) |
Showing 10 of 11
US Market Status
Market Closed — Opens Mon (64h 22m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access